Entrada Therapeutics Statistics
Total Valuation
TRDA has a market cap or net worth of $436.68 million. The enterprise value is $181.83 million.
Important Dates
The last earnings date was Thursday, February 26, 2026, before market open.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TRDA has 36.00 million shares outstanding. The number of shares has increased by 6.07% in one year.
| Current Share Class | 36.00M |
| Shares Outstanding | 36.00M |
| Shares Change (YoY) | +6.07% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | 1.09% |
| Owned by Institutions (%) | 42.11% |
| Float | 21.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.78 |
| Forward PS | 28.88 |
| PB Ratio | 1.39 |
| P/TBV Ratio | 1.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.53, with a Debt / Equity ratio of 0.17.
| Current Ratio | 12.53 |
| Quick Ratio | 12.20 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -39.13% and return on invested capital (ROIC) is -244.43%.
| Return on Equity (ROE) | -39.13% |
| Return on Assets (ROA) | -21.58% |
| Return on Invested Capital (ROIC) | -244.43% |
| Return on Capital Employed (ROCE) | -44.20% |
| Weighted Average Cost of Capital (WACC) | 3.19% |
| Revenue Per Employee | $167,243 |
| Profits Per Employee | -$945,724 |
| Employee Count | 152 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, TRDA has paid $924,000 in taxes.
| Income Tax | 924,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.75% in the last 52 weeks. The beta is -0.12, so TRDA's price volatility has been lower than the market average.
| Beta (5Y) | -0.12 |
| 52-Week Price Change | -0.75% |
| 50-Day Moving Average | 10.96 |
| 200-Day Moving Average | 8.02 |
| Relative Strength Index (RSI) | 56.25 |
| Average Volume (20 Days) | 201,742 |
Short Selling Information
The latest short interest is 908,901, so 2.52% of the outstanding shares have been sold short.
| Short Interest | 908,901 |
| Short Previous Month | 896,142 |
| Short % of Shares Out | 2.52% |
| Short % of Float | 4.16% |
| Short Ratio (days to cover) | 3.62 |
Income Statement
In the last 12 months, TRDA had revenue of $25.42 million and -$143.75 million in losses. Loss per share was -$3.47.
| Revenue | 25.42M |
| Gross Profit | -115.15M |
| Operating Income | -156.00M |
| Pretax Income | -142.83M |
| Net Income | -143.75M |
| EBITDA | -151.90M |
| EBIT | -156.00M |
| Loss Per Share | -$3.47 |
Full Income StatementBalance Sheet
The company has $295.70 million in cash and $50.93 million in debt, with a net cash position of $244.77 million or $6.80 per share.
| Cash & Cash Equivalents | 295.70M |
| Total Debt | 50.93M |
| Net Cash | 244.77M |
| Net Cash Per Share | $6.80 |
| Equity (Book Value) | 306.13M |
| Book Value Per Share | 8.50 |
| Working Capital | 281.80M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$128.51 million and capital expenditures -$1.04 million, giving a free cash flow of -$129.55 million.
| Operating Cash Flow | -128.51M |
| Capital Expenditures | -1.04M |
| Free Cash Flow | -129.55M |
| FCF Per Share | -$3.60 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -613.66% |
| Pretax Margin | -561.84% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TRDA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.07% |
| Shareholder Yield | -6.07% |
| Earnings Yield | -33.70% |
| FCF Yield | -30.37% |
Analyst Forecast
The average price target for TRDA is $20.00, which is 64.88% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.00 |
| Price Target Difference | 64.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 59.71% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TRDA has an Altman Z-Score of 1.17 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.17 |
| Piotroski F-Score | 2 |
